Diabetes (2004)

Once again, the 6th Annual Diabetes Conference brings together all the leading players in diabetes drug development.

Our top speakers will help you to evaluate the limitations of existing diabetes therapies. They will assist you in identifying where new advances are being made, and which approaches are best for you and your pipeline.

This Conference agenda is packed with actionable data that you can take away to enhance your own diabetes portfolio.

Speakers include: Novo Nordisk, Roche, Aventis, Pfizer, Lilly, Probiodrug, TNO Pharma, Arena Pharma, J&J, Abbott, Genzyme, Glaxo, Institute for Metabolic Research, ISIS, Ingenium and VTT.

This year's agenda includes two invaluable contributions from Pfizer by:

• Dr Michael Jirousek, Director & Head, Diabetes, Obesity Therapeutic Area, Pfizer
  
• Dr Andrew Swick, Director, Cardiovascular & Metabolic Diseases, Pfizer

• Dr Eric Lewis, Global Director, World Wide Development, GlaxoSmithKline
• Dr Monique Berwaer, Head, Metabolic Disease, Johnson & Johnson
• Prof Manfred Ganz, Head, Medical Assessment, Roche Diagnostics
• Dr Michael Trautmann, Medical Fellow, Eli Lilly & Company
• Dr Cristina Rondinone, Group Leader, Metabolic Diseases Research, Abbott Laboratories
• Dr Monica Einstein, Research Fellow, Merck
• Dr Cynthia Arbeeny, Vice President, Metabolic Diseases, Genzyme

• Diabetes treatment and future therapies
• Overcoming the limitations of current therapies
• The intersection of obesity, macronutrient regulation and type II
• How to idenfiy potential of GLP-1 compounds
• How to improve metabolic control
• DPPIV inhibitors
• AMP kinases
• 11 betaHSD enzyme inhibitors
• Animal models
• Identifying the most promising new pathways from lab investigations
• Using antisense technology to discover new diabetes drugs
• Novel diabetes related gene discovery
• Systems biology tools for diabetes research
• Insulin delivery without injection
• RNAi-based gene silencing
• New approaches to disease progression
• Future targets for pharmacological intervention
• Competitive and pricing challenges in the marketplace

• GLP-1 AND INCRETIN MIMETICS: Hear about Extenatide and pre-clinical and clinical experiences with it
• DPP lV INHIBITION AND SAFETY: Improving metabolic control and the long term effects of DPP IV inhibition on different parameters of type ll diabetes
• NOVEL APPROACHES AND ALTERNATIVE METHODS OF ADMINISTRATION: Learn about promising new pathways being investigated in the lab
• DEVELOPING ANTISENSE INHIBITORS FOR METABOLIC DISEASES: Assess how technology is being applied to treat metabolic disorders
• INDUSTRY EXPERTS: Network with leaders in the field and gain an insight into their experiences